The standard for heart failure (first revision) of the Dutch Cllege of General Practitioners;NHG-Standaard Hartfalen, eerste herziening

Huisarts en Wetenschap

Volumn 48, Issue 2, 2005, Pages 64-76

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUMETANIDE; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IBOPAMINE; LOSARTAN; METOPROLOL; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; VERAPAMIL;

DISEASE CLASSIFICATION; GENERAL PRACTITIONER; HEART FAILURE; HUMAN; MEDICAL SOCIETY; NETHERLANDS; PRACTICE GUIDELINE; REVIEW; STANDARD;

EID: 13544274050     PISSN: 00187070     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Annane D, Bellissant E, Pussard E, Asmar R, Lacombe F, Lanata E, et al. Placebo-controlled, randomized, double-blind study of intravenous enalaprilat efficacy and safety in acute cardiogenic pulmonary edema. Circulation 1996;94:1316-24.
2. Anonymus. Digoxin: new answers; new questions. Lancet 1989;2:79-80.
3. Anonymus. On bedresting in heart failure. Lancet 1990;336:975-6.
4. Badgett RG, Mulrow CD, Otto PM, Ramirez G. How well can the chest radiograph diagnose left ventricular dysfunction? J Gen Intern Med 1996;11:625-34.
5. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000;160:685-93.
6. Banerjee P, Banerjee T, Khand A, Clark AL, Cleland JG. Diastolic heart failure: neglected or misdiagnosed? J Am Coll Cardiol 2002;39:138-41.
7. Baughman KL. B-type natriuretic peptide - a window to the heart. N Engl J Med 2002;347:158-9.
8. Bauwens LJ, Copper MP, Schmidt JT. Levensbedreigend angio-oedeem als bijwerking van angiotensine-'converting'-enzym (ACE)-remmers. Ned Tijdschr Geneeskd 1995;139:674-7.
9. Bongers FJM, Bakx JC, Heesakkers WHJ, Van de Lisdonk EH. De patient met hartfalen in de huisartspraktijk. Hart Bull 2003;34:4-7.
10. Borst JGG, Molhuysen JA. Exact determination of the central venous pressure by a simple clinical method. Lancet 1952;ii:304-9.
11. Braunwald E. Heart failure. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison's principles of internal medicine. New York: McGraw-Hill, 2001a.
12. Braunwald E. Normal and abnormal myocardial function. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison's principles of internal medicine. New York: McGraw-Hill, 2001b.
13. Canas F, Tanasijevic MJ, Ma'luf N, Bates DW. Evaluating the appropriateness of digoxin level monitoring. Arch Intern Med 1999;159:363-8.
14. Cardarelli R, Lumicao TG Jr. B-type natriuretic peptide: a review of its diagnostic, prognostic, and therapeutic monitoring value in heart failure for primary care physicians. J Am Board Fam Pract 2003;16:327-33.
15. Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Brighetti G, et al. Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 2002;40:304-10.
16. Cost B, Grobbee DE, Moons KGM, Van der Schoot-van Venrooy I, Balk AHMM, Man in 't Veld AJ, et al. Diagnosis in patients suspected of heart failure: importance of neurohormones. In: Cost B. Heart failure in the elderly [Proefschrift]. Rotterdam: Erasmus Universiteit, 2000:67-82.
17. Cotter G, Metzkor E, Kaluski E, Faigenberg Z, Miller R, Simovitz A, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 1998;351:389-93.
18. Cowie MR, Jourdain P, Maisel A, Dahlstrom U, Follath F, Isnard R, et al. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J 2003;24:1710-8.
19. Criteria Committee of the New York Heart Association. Diseases of the heart and blood vessels. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. Boston: Little, Brown & Co, 1994.
20. Dargie HJ, McMurray JJ. Diagnosis and management of heart failure. BMJ 1994;308:321-8.
21. Davie AP, Francis CM, Love MP, Caruana L, Starkey IR, Shaw TR, et al. Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. BMJ 1996;312:222.
22. Davie AP, Francis CM, Caruana L, Sutherland GR, McMurray JJ. Assessing diagnosis in heart failure: which features are any use? QJM 1997;90:335-9.
23. Davis RC, Hobbs FD, Kenkre JE, Roalfe AK, Hare R, Lancashire RJ, et al. Prevalence of left ventricular systolic dysfunction and heart failure in high risk patients: community based epidemiological study. BMJ 2002;325:1156.
24. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336: 525-33.
25. Doust JA, Glasziou PP, Pietrzak E, Dobson AJ. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med 2004;164:1978-84.
26. Drazner MH, Rame JE, Stevenson LW, Dries DL. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med 2001;345:574-81.
27. Dukes MNG. Meyler's Side effects of drugs. Amsterdam: Elsevier, 1996.
28. Faris R, Flather M, Purcell H, Henein M, Poole-Wilson P, Coats A. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J Cardiol 2002;82:149-58.
29. Farmacotherapeutisch kompas. Amstelveen: CVZ, 2004; http://www.fk.cvz.nl.
30. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355:1575-81.
31. Gaasch WH. Diagnosis and treatment of heart failure based on left ventricular systolic or diastolic dysfunction. JAMA 1994;271:1276-80.
32. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273:1450-6.
33. Geijer RMM, Walma EP. Medicamenteuze behandeling van hartfalen: een herwaardering van bètablokkers, spironolacton en digoxine. Huisarts Wet 2000;43:163-6.
34. Gheorghiade M, Zarowitz BJ. Review of randomized trials of digoxin therapy in patients with chronic heart failure. Am J Cardiol 1992;69:48G-62G.
35. Heerdink ER. Clustering of drug use in the elderly: population-based studies into prevalence and outcomes [Proefschrift]. Utrecht: Universiteit Utrecht, 1995.
36. Herings RMC, De Boer A, Stricker BH, Leufkens HG, Porsius AJ. ACE-remmers vergroten het risico op hypoglykemie bij diabetici. Ned Tijdschr Geneeskd 1996;140:432-6.
37. Hoffman JR, Reynolds S. Comparison of nitroglycerin, morphine and furosemide in treatment of presumed pre-hospital pulmonary edema. Chest 1987;92:586-93.
38. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004;43:317-27.
39. Hood WB Jr, Dans AL, Guyatt GH, Haeschke R, McMurray JJV. Digitalis for treatment of congestive heart failure in patients in sinus rhythm (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Chichester: Wiley.
40. Huls M, Giessen P. De behandeling van acuut hartfalen in de huisartsenpraktijk. Huisarts Wet 2000;43:522-6.
41. Informatorium medicamentorum. Den Haag: WINAp/KNMP, 2004.
42. Jaarsma T, Dracup K, Walden J, Stevenson LW. Sexual function in patients with advanced heart failure. Heart Lung 1996;25:262-70.
43. Jaarsma T, Abu-Saad HH, Dracup K, Halfens R. Self-care behaviour of patients with heart failure. Scand J Caring Sci 2000;14:112-9.
44. Jessup M, Brozena S. Heart failure. N Engl J Med 2003;348:2007-18.
45. Jong P, Demers C, McKelvie RS, Liu PP. Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J Am Coll Cardiol 2002;39:463-70.
46. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med 2002;347:305-13.
47. Kitzman DW, Gardin JM, Gottdiener JS, Arnold A, Boineau R, Aurigemma G, et al. Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol 2001;87:413-9.
48. Kitzman DW. Diastolic heart failure in the elderly. Heart Fail Rev 2002;7:17-27.
49. Klein LW, Visocan BJ. The role of restriction of sodium intake in the treatment of heart failure in the elderly. J Am Geriatr Soc 1984;32:353-5.
50. Kwaliteitsinstitu ut voor de gezondheidszorg CBO. http://www.cbo.nl/ product/richtlijnen/pdf/ hartfalen2002.
51. Lindenfeld J, Krause-Steinrauf H, Salerno J. Where are all the women with heart failure? J Am Coll Cardiol 1997;30:1417-9.
52. Lloyd-Williams F, Mair FS, Leitner M. Exercise training and heart failure: a systematic review of current evidence. Br J Gen Pract 2002;52:47-55.
53. Mosterd A, Deckers JW, Hoes AW, Nederpel A, Smeets A, Linker DT, et al. Classification of heart failure in population based research: an assessment of six heart failure scores. Eur J Epidemiol 1997;13:491-502.
54. Mosterd A, Hoes AW, De Bruyne MC, Deckers JW. Linker DT, Hofman A, et al. Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. Eur Heart J 1999;20:447-55.
55. Mosterd A, Cost B, Hoes AW, De Bruijne MC, Deckers JW, Hofman A, et al. The prognosis of heart failure in the general population: The Rotterdam Study. Eur Heart J 2001;22:1318-27.
56. Nielsen OW, Hansen JF, Hilden J, Larsen CT, Svanegaard J. Risk assessment of left ventricular systolic dysfunction in primary care: cross sectional study evaluating a range of diagnostic tests. BMJ 2000;320:220-4.
57. Packer M. Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure? Circulation 2003;108:2950-3.
58. Pahor M, Guralnik JM, Gambassi G, Bernabei R, Carosella L, Carbonin P. The impact of age on risk of adverse drug reactions to digoxin. For The Gruppo Italiano di Farmacovigilanza nell' Anziano. J Clin Epidemiol 1993;46:1305-14.
59. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003a;349:1893-906.
60. Pfeffer MA, Swedberg K, Granger CB, Held R McMurray JJ, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003b;362:759-66.
61. Philbin EF, Rocco TA Jr., Lindenmuth NW, Ulrich K, Jenkins PL. Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. Am J Med 2000;109:605-13.
62. Piepoli MF, Davos C, Francis DP, Coats AJ. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ 2004;328:189.
63. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
64. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13.
65. RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure: the Randomized Aldactone Evaluation Study (RALES). Am J Cardiol 1996;78:902-7.
66. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003;289:871-8.
67. Redfield MM, Jacobsen SJ, Burnett JC, Jr., Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003;289:194-202.
68. Remkes PAJ. Niet-invasief cardiaal functie-onderzoek op verzoek van de huisarts [Proefschrift]. Zutphen: Koninklijke Wöhrmann, 1997.
69. Rihal CS, Davis KB, Kennedy JW, Gersh BJ. The utility of clinical, electrocardiographic, and roentgenographic variables in the prediction of left ventricular function. Am J Cardiol 1995;75:220-3.
70. RJVM. Nationaal kompas volksgezondheid; http://www.rivm.nl, geraadpleegd 4 Oktober 2004.
71. Rossi P, Physical training in patients with congestive heart failure. Chest 1992;101:350S-3S.
72. Rutten FH, Grobbee DE, Hoes AW. Differences between general practitioners and cardiologists in diagnosis and management of heart failure: a survey in every-day practice. Eur J Heart Fail 2003;5:337-44.
73. Salpeter SR, Ormiston TM, Salpeter EE, Poole P, Cates C. Cardioselective beta-blockers for chronic obstructive pulmonary disease (Cochrane Review). In: The Cochrane Library, Issue 1, 2004. Chichester: Wiley, 2004a.
74. Salpeter SR, Ormiston TM, Salpeter EE. Wood-Baker R. Cardioselective beta-blockers for reversible airway disease (Cochrane Review). In: The Cochrane Library, Issue 1, 2004. Chichester: Wiley, 2004b.
75. Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 1992;20:301-6.
76. Shibata MC, Flather MD, Wang D. Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. Eur J Heart Fail 2001;3:351-7.
77. Singer GG, Brenner BM. Fluid and electrolyte disturbances. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison's principles of internal medicine. New York: McGraw-Hill, 2001.
78. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
79. Struthers AD, Morris AD. Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet 2002;359:1430-2.
80. Suskin N, Sheth T, Negassa A, Yusuf S. Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. J Am Coll Cardiol 2001;37:1677-82.
81. Sytkowski PA, Kannel WB, D'Agostino RB. Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study. N Engl J Med 1990;322:1635-41.
82. Thomas IT, Kelly RF, Thomas SJ, Stamos TD, Albasha K, Parrillo JE, et al. Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure. Am J Med 2002;112:437-45.
83. Uren NG, Lipkin DP. Exercise training as therapy for chronic heart failure. Br Heart J 1992;67:430-3.
84. Van der Linden MW, Westert GP, De Bakker DH, Schellevis FG. Tweede Nationale Studie naar ziekten en Verrichtingen in de huisartspraktijk: klachten en aandoeningen in de bevolking en in de huisartspraktijk. http://www.nivel.nl/ nationale Studie. 2004.
85. Wynne J, Braunwald E. The cardiomyopathies and myocarditides. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison's principles of internal medicine. New York: McGraw-Hill, 2001.
86. Yusuf S, Thom T, Abbott RD. Changes in hypertension treatment and in congestive heart failure mortality in the United States. Hypertension 1989;13:174-179.
87. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777-81.
88. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part 1: diagnosis, prognosis, and measurements of diastolic function. Circulation 2002a;105:1387-93.
89. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation 2002b;105:1503-8.